To get tirzepatide online, start with a medical visit—not a checkout page. Complete a tirzepatide-specific intake, verify where you are physically located, and submit your health history and current medications. A clinician authorized to practice in that state reviews the request. If treatment fits, the clinician writes a prescription and a licensed pharmacy dispenses either a brand product or, in limited patient-specific circumstances, a compounded formulation. Payment alone should never trigger a shipment.
That is the practical difference between prescription telehealth and a website selling an unverified vial. The screen is not the safeguard. The accountable clinician and identifiable pharmacy are.
Three legitimate routes to tirzepatide online
| Route | Who makes the clinical decision | What may be dispensed | How payment usually works |
|---|---|---|---|
| In-person care | A primary-care clinician, obesity-medicine clinician, or endocrinologist | Mounjaro or Zepbound through a retail or mail pharmacy | Insurance or cash |
| Telehealth for a brand product | A clinician authorized to practice where the patient is located | Mounjaro or Zepbound through a retail, mail, or manufacturer-linked pharmacy | Insurance or self-pay |
| Telehealth for a compounded formulation | A reviewing clinician documents the patient-specific decision | A prescription prepared by a licensed compounding pharmacy | Usually direct pay |
The brand depends on the condition being treated. FDA describes Mounjaro for blood-sugar control in adults with type 2 diabetes alongside diet and exercise. Zepbound's weight-management criteria include an initial BMI of at least 30, or at least 27 with a weight-related condition; its current 2026 label also covers moderate-to-severe obstructive sleep apnea in adults with obesity. A brand self-pay program is a fulfillment and pricing channel, not a way around clinical review.
For telehealth, the patient's location at the time of care matters. State rules may require a full license, compact privilege, reciprocity, or telehealth registration. The federal cross-state licensure guide advises providers to verify location and consent before the appointment. This is why a credible intake asks where you are, even when a search for "tirzepatide near me" leads to a nationwide service.
What the tirzepatide intake actually asks
Expect questions about height, weight history, treatment goal, weight-related conditions, type 2 diabetes, and prior weight-management treatment. The safety screen should also cover current prescriptions and supplements, allergies, pregnancy plans, and prior problems involving the pancreas, gallbladder, kidneys, stomach emptying, or diabetic retinopathy.
Two histories deserve a direct answer: personal or family history of medullary thyroid carcinoma, and multiple endocrine neoplasia syndrome type 2. They are contraindications in the Zepbound label. A prior serious allergic reaction to tirzepatide is another contraindication. Insulin or a sulfonylurea matters because the combination can alter the low-blood-sugar risk. Planned surgery matters because delayed stomach emptying changes the anesthesia conversation.
A questionnaire cannot promise approval. It gives the clinician enough information to decide whether the requested medication, product route, and follow-up plan make medical sense. The clinician may request records, recent labs, or a live visit before deciding.
Why the treatment goal changes the prescription
The evidence comes from different patient groups, which is one reason the intake asks whether the goal is weight management or diabetes care. In SURMOUNT-1, 2,539 adults with obesity or overweight and a weight-related complication, without diabetes, were randomized for 72 weeks. Mean weight change was −15.0%, −19.5%, and −20.9% across the three tirzepatide groups versus −3.1% with placebo (Jastreboff et al., NEJM, 2022).
SURPASS-2 enrolled 1,879 adults with type 2 diabetes for 40 weeks. Mean HbA1c change was −2.01, −2.24, and −2.30 percentage points across the tirzepatide groups versus −1.86 points with semaglutide 1 mg (Frías et al., NEJM, 2021). Those are trial results for the products and protocols studied, not a forecast for an individual and not evidence that every compounded preparation is equivalent.
Brand self-pay is still a prescription route
Someone paying without insurance can ask a clinician to send a Zepbound prescription to a participating pharmacy or LillyDirect. As checked in August 2026, the manufacturer's current self-pay page lists starting monthly prices of $299 for 2.5 mg, $399 for 5 mg, and $449 for 7.5 mg through 15 mg when higher-dose refills meet the program's 45-day rule. Eligibility and terms apply, and the program can change.
The important sequence is prescriber first, pharmacy second. A manufacturer program does not decide whether the medication is appropriate. Insurance prior authorization is another separate decision: a health plan may ask for diagnostic, BMI, comorbidity, or prior-treatment documentation even after a clinician writes the prescription. The tirzepatide cost comparison explains those payment routes in more detail.
Where compounded tirzepatide fits in 2026
Promise's tirzepatide is dispensed as a compounded medication, which is different from an FDA-approved product: the formulation offered here—tirzepatide with vitamin B12—is not FDA-approved. The finished preparation does not undergo FDA premarket review for safety, effectiveness, or quality. It is also not a generic version of Mounjaro or Zepbound.
FDA reconfirmed the tirzepatide injection shortage was resolved on December 19, 2024. The shortage-related enforcement periods ended in 2025. As of August 2026, the agency's April 2026 compounding update says section 503A compounding must be based on a prescription for an identified patient and restricts regular or inordinate production of products that are essentially copies. The update describes an exception when a prescriber determines and documents that a change produces a significant difference for that individual. Adding another ingredient by itself does not establish that difference.
A licensed provider may still prescribe a compounded formulation when patient-specific facts and applicable compounding rules support it; that decision is between the patient and the doctor. Regulatory status is a fact to understand, not a substitute for that clinical decision.
What happens after the provider says yes
At Promise, a licensed provider reviews every request and either prescribes or declines on medical eligibility; not everyone qualifies. If a prescription is written, a licensed U.S. compounding pharmacy prepares tirzepatide with vitamin B12 as an injectable vial and sends it in temperature-safe packaging. The pharmacy label and instructions identify the concentration, storage requirements, and measurement method for that preparation. The prescriber sets the actual dose and follow-up plan.
Brand products arrive in manufacturer packaging as the presentation prescribed. A compounded vial should arrive with the patient's name, dispensing pharmacy, ingredients or concentration, storage directions, and use instructions. FDA has received complaints about injectable GLP-1 products arriving warm or with inadequate cold packs, and its current safety page also documents fraudulent labels naming pharmacies that did not prepare the product. A warm, damaged, unclear, or mismatched shipment is a reason to contact the dispensing pharmacy before use.
The legitimacy check before you submit an intake
A real service tells you who will review the request, confirms the clinician can practice where you are, identifies the dispensing pharmacy after prescribing, and keeps follow-up available. It does not sell a vial first and add a medical questionnaire as decoration.
The tirzepatide product page shows Promise's product-specific intake route. For the state-law side of a virtual visit, see why telehealth licensure follows the patient. For the safety questions likely to shape follow-up, review tirzepatide side effects. The consistent thread is simple: the medication follows the prescription, and the prescription follows a clinician's decision.